Taleo Fasihah, Taleo George, Graves Patricia M, Wood Peter, Kim Sung Hye, Ozaki Masayo, Joseph Hayley, Chu Brian, Pavluck Alex, Yajima Aya, Melrose Wayne, Ichimori Kazuyo, Capuano Corinne
Government of Vanuatu, Vector Borne Disease Control Unit, Port Vila, Vanuatu.
College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns and Townsville, Queensland Australia.
Trop Med Health. 2017 Jun 16;45:18. doi: 10.1186/s41182-017-0057-6. eCollection 2017.
Vanuatu was formerly highly endemic for lymphatic filariasis (LF), caused by and transmitted by mosquitoes. After a baseline survey showing 4.8% antigen prevalence in 1998, the country conducted nationwide (in one implementation unit) annual mass drug administration (MDA) with albendazole and diethylcarbamazine citrate from 2000 to 2004 and achieved prevalence of 0.2% by 2006 in a representative nationwide cluster survey among all age groups.
Post MDA surveillance was conducted from 2006 to 2012. After MDA, the country was divided for surveillance into three evaluation units (EUs) formed by grouping provinces according to baseline prevalence: EU1: Torba, Sanma and Malampa; EU2: Penama; EU3: Shefa and Tafea. The study compiled all past data and information on surveys in Vanuatu from the country programme. This paper reviews the surveillance activities done after stopping MDA to validate the interruption of transmission and elimination of LF as a public health problem.
Post-MDA surveillance consisting of at least three transmission assessment surveys (TAS) in each of the three EUs was conducted between 2006 and 2012. Sentinel and spot check surveys identified a few villages with persistent high prevalence; all antigen positive cases in these sites were treated and additional targeted MDA conducted for 3 years in 13 villages in one area of concern. All three EUs passed all TAS in 2007, 2010 and 2012 respectively, with no positives found except in EU2 (Penama province) in 2012 when 2 children tested positive for circulating filariasis antigen. Assessment of the burden of chronic filariasis morbidity found 95 cases in 2003 and 32 remaining cases in 2007, all aged over 60 years.
Vanuatu has achieved validation of elimination of LF as a public health problem. Post-validation surveillance is still recommended especially in formerly highly endemic areas.
瓦努阿图曾是淋巴丝虫病(LF)的高度流行地区,由班氏吴策线虫和帝汶布鲁线虫引起,通过按蚊传播。1998年的基线调查显示抗原流行率为4.8%,该国于2000年至2004年在全国范围(作为一个实施单位)开展了使用阿苯达唑和枸橼酸乙胺嗪的年度群体服药(MDA),并在2006年针对所有年龄组开展的具有代表性的全国整群调查中使流行率降至0.2%。
2006年至2012年开展了MDA后监测。MDA之后,该国根据基线流行率将省份分组,划分为三个评估单位(EUs)进行监测:欧盟1:托尔巴、桑马和马朗巴;欧盟2:佩纳马;欧盟3:谢法和塔菲亚。该研究汇总了该国项目中瓦努阿图过去所有调查的数据和信息。本文回顾了停止MDA后开展的监测活动,以验证传播阻断情况以及将LF作为公共卫生问题予以消除的情况。
2006年至2012年期间,在三个EUs中的每个单位开展了至少三次传播评估调查(TAS)的MDA后监测。哨点和抽查调查发现了一些流行率持续较高的村庄;对这些地点所有抗原阳性病例进行了治疗,并在一个关注地区的13个村庄进行了为期3年的额外针对性MDA。所有三个EUs分别在2007年、2010年和2012年通过了所有TAS,除2012年欧盟2(佩纳马省)有2名儿童循环丝虫抗原检测呈阳性外,未发现阳性病例。对慢性丝虫病发病负担的评估发现,2003年有95例,2007年有32例剩余病例,所有病例年龄均超过60岁。
瓦努阿图已证实将LF作为公共卫生问题予以消除。仍建议开展验证后监测,特别是在以前的高度流行地区。